Optimized strategy for rapid cytochrome P450 2D6 genotyping by real-time long PCR

被引:33
作者
Müller, B [1 ]
Zöpf, K [1 ]
Bachofer, J [1 ]
Steimer, W [1 ]
机构
[1] Tech Univ Munich, Klinikum Rechts Isar, Inst Klin Chem & Pathobiochem, D-81675 Munich, Germany
关键词
D O I
10.1373/49.10.1624
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 [基础医学];
摘要
Background: Because of genetic polymorphisms, cytochrome P450 2D6 (Cyp2D6) activity in humans varies widely and alters the metabolism of commonly used drugs such as antidepressants, neuroleptics, and cardioactive agents. Severe adverse effects or resistance to therapy may result. Methods: We performed long PCR on the LightCycler(TM). and used the product as a template for a previously validated multiplex PCR that examines the *3, *4, *6, *7, and *8 alleles of Cyp2D6. We used real-time PCR to identify the *5 null allele and duplication of Cyp2D6 with detection by either hybridization probes or SYBR Green(R). The *2 -1584 C/G polymorphism and the *35 allele were identified by PCR with detection by hybridization probes. Products of all PCRs were visualized with gel electrophoresis using a 0.7-1.5% agarose gel and ethidium bromide. Samples containing the *35 allele were analyzed in parallel by digestion with NlaIII, MslI, and BstXI and SmaI. We analyzed samples from volunteers and patients (105 samples for deletion and duplication and 116 samples for preamplification). Of those samples, 59 were from depressive inpatients taking part in a trial not yet published. Results: Identical genotyping results for both real-time and conventional PCR were obtained and verified by gel electrophoresis. Use of long-PCR methods on the LightCycler enabled comprehensive analysis of all relevant polymorphisms of the Cyp2D6 gene in 1 working day with a hands-on time of similar to3-4 h. Conclusions: This is the first description of a successful long-PCR application on the LightCycler and the fastest technique for amplification and specific detection of a PCR product of comparable length. The method appears suitable for large clinical and epidemiologic studies. (C) 2003 American Association for Clinical Chemistry.
引用
收藏
页码:1624 / 1631
页数:8
相关论文
共 22 条
[1]
PREVALENCE OF CYP2D6 GENE DUPLICATION AND ITS REPERCUSSION ON THE OXIDATIVE PHENOTYPE IN A WHITE-POPULATION [J].
AGUNDEZ, JAG ;
LEDESMA, MC ;
LADERO, JM ;
BENITEZ, J .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 57 (03) :265-269
[2]
In-vitro analysis of the contribution of CYP2D6.35 to ultrarapid metabolism [J].
Allorge, D ;
Harlow, J ;
Boulet, O ;
Hayhurst, GP ;
Chowdry, J ;
Roth, E ;
Crewe, K ;
Lo-Guidice, JM ;
Lhermitte, M ;
Broly, F ;
Tucker, GT ;
Ellis, SW .
PHARMACOGENETICS, 2001, 11 (08) :739-741
[3]
DAHL ML, 1995, J PHARMACOL EXP THER, V274, P516
[4]
INHERITED AMPLIFICATION OF AN ACTIVE GENE IN THE CYTOCHROME-P450 CYP2D LOCUS AS A CAUSE OF ULTRARAPID METABOLISM OF DEBRISOQUINE [J].
JOHANSSON, I ;
LUNDQVIST, E ;
BERTILSSON, L ;
DAHL, ML ;
SJOQVIST, F ;
INGELMANSUNDBERG, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (24) :11825-11829
[5]
Ultrarapid metabolizers of debrisoquine: Characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene [J].
Lovlie, R ;
Daly, AK ;
Molven, A ;
Idle, JR ;
Steen, VM .
FEBS LETTERS, 1996, 392 (01) :30-34
[6]
Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype:: a role for the CYP2D6*35 allele in ultrarapid metabolism? [J].
Lovlie, R ;
Daly, AK ;
Matre, GE ;
Molven, A ;
Steen, VM .
PHARMACOGENETICS, 2001, 11 (01) :45-55
[7]
Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: Characterization of 48 mutations and 53 alleles, their frequencies and evolution [J].
Marez, D ;
Legrand, M ;
Sabbagh, N ;
LoGuidice, JM ;
Spire, C ;
Lafitte, JJ ;
Meyer, UA ;
Broly, F .
PHARMACOGENETICS, 1997, 7 (03) :193-202
[8]
MULLER B, 2001, CLIN CHEM, V47, pA240
[9]
Prospective GYP2D6 genotyping as an exclusion criterion for enrollment of a phase III clinical trial [J].
Murphy, MP ;
Beaman, ME ;
Clark, LS ;
Cayouette, M ;
Benson, L ;
Morris, DM ;
Polli, JW .
PHARMACOGENETICS, 2000, 10 (07) :583-590
[10]
Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6 [J].
Raimundo, S ;
Fischer, R ;
Eichelbaum, M ;
Griese, EU ;
Schwab, M ;
Zanger, UM .
PHARMACOGENETICS, 2000, 10 (07) :577-581